Using a basket trial setting of pan-cancer BRAF-V600E cell lines, we developed an O-PLS model to predict tumor cell sensitivity to vemurafenib and identified co-treatments to overcome inherent resistance. The gene discussed is BRAF; the disease is neoplasm.